Teleflex Inc Stock Price, News & Analysis

Teleflex reported second quarter 2022 revenues of $704.5 million, a 1.3% decline year-over-year, but a 2.3% increase on a constant currency basis. GAAP diluted EPS rose to $2.23, up from $1.76 in the previous year. However, the company reduced its 2022 revenue growth guidance to (0.45% to 0.55%) and GAAP EPS guidance to $8.04 to $8.44. The decline was attributed mainly to challenges in the Interventional Urology segment and foreign currency impacts. Despite this, Teleflex remains focused on long-term growth strategies in its high-growth portfolio.

Teleflex Incorporated (NYSE: TFX) is participating in the Pocono Raceway NASCAR event from July 22-24, 2022, to raise awareness about benign prostatic hyperplasia (BPH). BPH affects over 14 million men, causing symptoms like urinary frequency and urgency. The company emphasizes the importance of routine screenings, especially after many delayed medical care during the COVID-19 pandemic. At the event, Teleflex will feature the UroLift® System, a minimally invasive treatment for BPH, and host patient ambassadors to share personal experiences.

Teleflex Incorporated (NYSE: TFX) is set to host a conference call on July 28, 2022, at 8:00 a.m. ET to discuss its second quarter financial results and provide an operational update. Participants can pre-register using a provided link or access the live audio webcast on the company’s website. An audio replay will be available after the call. Teleflex is a global provider of medical technologies aimed at improving health outcomes, with products in various medical fields, including vascular access and anesthesia.

Teleflex announced promising findings at the 37th Annual European Association of Urology Congress regarding its UroLift System for treating benign prostatic hyperplasia (BPH). Key results showed that 79% of over 300 subjects reported a reduction in their IPSS symptom severity 12 months post-treatment. Furthermore, symptom improvement was independent of prostate size or shape. The study also highlighted that patients treated with UroLift required significantly fewer prescriptions post-surgery compared to those undergoing more invasive procedures.

Teleflex Incorporated (NYSE: TFX) announced the first patient enrolled in the MANTA Ultra Study, aimed at assessing the safety of the MANTA® Vascular Closure Device using ultrasound guidance during elective TAVR procedures. This prospective study will involve up to 150 patients across 15 sites in the US and Canada, focusing on reducing access site complications associated with large bore procedures. Key endpoints include major and minor vascular complications within 30 days, along with various effectiveness measures. The study could enhance procedural flexibility for surgeons.

Teleflex Incorporated (NYSE: TFX) announced the launch of its Arrow Pressure Injectable Midline Catheter in Europe, the Middle East, and Africa. This new catheter, featuring brightly colored hubs to enhance clinician identification and minimize infusion errors, is available in 1-lumen and 2-lumen configurations. Key features include a TAPERFREE design to reduce venous stasis and procedural efficiency enhancements. The device allows for pressure injection up to 5 mL/second, improving patient care and reducing delays in diagnostics.

Teleflex (NYSE: TFX) provided a business update during its 2022 Analyst & Investor Day in New York City on May 20, 2022. The company outlined its growth strategy for 2023-2025, targeting a compounded annual constant currency revenue growth rate of 6-7%. Teleflex expects adjusted earnings per share to increase to between $13.70 and $14.30 for 2022. The company anticipates generating free cash flow of at least $1.7 billion from 2023 to 2025, with a focus on margin improvement and strategic acquisitions. The full year revenue growth for 2022 is projected to be between 2.3% and 3.8%.

Teleflex Incorporated has announced the National Medical Products Administration (NMPA) approval for its UroLift® System in China, aimed at treating benign prostatic hyperplasia (BPH). This minimally invasive treatment offers symptom relief with same-day outpatient procedures. CEO Liam Kelly highlighted this as a critical step in the company's international expansion, providing treatment options for over 25 million men in China diagnosed with BPH. The company anticipates commercialization by Q4 2022.